AVI BioPharma to Present at UBS Global Specialty Pharmaceuticals Conference
Posted on: Friday, 21 April 2006, 09:00 CDT
AVI BioPharma, Inc. (Nasdaq:AVII), today announced that on Monday, April 24, 2006, Alan P. Timmins, AVI's president and COO, will present the company's overall strategy and progress to date at the UBS Global Specialty Pharmaceuticals Conference to be held at the Grand Hyatt New York. The presentation will take place at 12 p.m. EDT in Ballroom E.
About AVI BioPharma
AVI BioPharma develops therapeutic products for the treatment of life-threatening diseases using third-generation NEUGENE antisense drugs. AVI's lead NEUGENE antisense compound is designed to target cell proliferation disorders, including cardiovascular restenosis, cancer and polycystic kidney disease. In addition to targeting specific genes in the body, AVI's antiviral program uses NEUGENE antisense compounds to combat disease by targeting single-stranded RNA viruses, including West Nile virus, hepatitis C virus, dengue virus, Ebola virus and influenza A virus. AVI has introduced a NEUGENE-based exon-skipping technology called ESPRIT therapy. More information about AVI is available on the company's Web site at http://www.avibio.com.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company's Securities and Exchange Commission filings.
Source: Business Wire
Related Articles
- AVI BioPharma Publishes Preclinical Data Showing NEUGENE Antisense Inhibition of Multiple Strains of Influenza A Virus
- AVI BioPharma Initiates NEUGENE Antisense Clinical Program in Coronary Artery Bypass Grafting
- AVI BioPharma Presents Positive Preclinical Data Evaluating NEUGENE Antisense Compounds Against Influenza A Virus and the E. Coli Bacteria
- AVI BioPharma Reports Preclinical Data Against Multiple Strains of Influenza; NEUGENE Antisense Efficacy Against Influenza Strains Reported at the International Conference on Antiviral Research
- AVI BioPharma Reports Favorable Safety and Pharmacokinetic Data From Its Clinical Trial Targeting Hepatitis C Virus; NEUGENE Antisense Compound Was Well-Tolerated and Exhibited Favorable Pharmacokinetic Parameters
- CORRECTING and REPLACING AVI BioPharma Updates Results From Department of Defense Funded Collaborative Programs; NEUGENE Antisense Agents Effective at Combating Ebola and Marburg Viruses and Ricin and Anthrax Toxins
- AVI BioPharma Announces Publication of SARS NEUGENE Antisense Studies in the Journal of Virology
- AVI BioPharma Presents Positive Results With NEUGENE Antisense Drugs At the American Association for Cancer Research Meeting
- AVI BioPharma Updates Third-Generation NEUGENE Antisense Program; Research, Preclinical and Clinical Trial Highlights Demonstrate Progress
- AVI BioPharma and USAMRIID Announce NEUGENE Antisense Drug Demonstrates Efficacy Against Ebola Virus
 |
 |
User Comments (0)
RSS Feeds